Posted by Michael Wonder on 20 Feb 2026
Savara announces the US FDA filed the Molbreevi biologics license application in auto-immune pulmonary alveolar proteinosis
20 February 2026 - Savara announced the FDA has filed for review the BLA for Molbreevi as a therapy to treat patients with auto-immune pulmonary alveolar proteinosis.
The FDA granted priority review with a PDUFA action date of 22 August 2026.
